UNSPSC 51181919: Clomifene or clomiphene

This classification denotes an antiestrogen and angiogenesis activator inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1HRS458QU2. European Medicines Agency schedules Clomifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06722MIG. Clomifene generally arises in the molecular formula C26H28CLNO. The term 'clomifene' is a Hazardous Substances Data Bank designation. CLOMIFENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Clomifene or clomiphene bears US NLM identifiers UMLS ID C0009008 and NCI Concept Code C61607. SMILES: CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\C2=CC=CC=C2)/CL)/C3=CC=CC=C3.

UNSPSC 51181919 Clomifene or clomiphene is a Commodity code representing pharmaceutical active ingredients and finished pharmaceutical products that state and local health systems procure through multistate cooperative purchasing agreements. The most recent activity shows state and local governments buying generic pharmaceuticals and over-the-counter products in bulk through established wholesaler networks, with pricing and product specifications negotiated directly with manufacturers who must meet FDA compliance, current Good Manufacturing Practices (cGMP), and Drug Supply Chain Security Act (DSCSA) certification. Issuing bodies soliciting under this code include state health departments and multistate cooperative purchasing alliances administering agreements on behalf of multiple participating state and local government facilities, including health agencies, public hospitals, and affiliated healthcare delivery systems across multiple states.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (RFP S1070000015802) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota, Oregon, and other participating jurisdictions. The proposal due date is March 26, 2026, with a question cutoff of February 18, 2026. Awarded vendors must establish relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), comply with a 3 percent administrative fee, provide comprehensive pricing data in specified EDI-compatible formats with National Drug Codes (NDC) and product specifications, maintain insurance coverage including commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, and accept performance penalties ranging from $200 to $1,500 per violation. The contract term is two years for new responders with optional extensions, or through June 30, 2028, for incumbent vendors whose amendments align with existing expiration dates.